{"id":460,"date":"2020-03-21T11:17:34","date_gmt":"2020-03-21T11:17:34","guid":{"rendered":"http:\/\/new.patterncomputer.com\/?p=460"},"modified":"2022-09-26T17:12:45","modified_gmt":"2022-09-26T17:12:45","slug":"revolutionary-machine-learning-company-identifies-two-possible-treatments-for-intractable-breast-cancer-type","status":"publish","type":"post","link":"http:\/\/new.patterncomputer.com\/revolutionary-machine-learning-company-identifies-two-possible-treatments-for-intractable-breast-cancer-type\/","title":{"rendered":"Revolutionary Machine Learning Company Identifies Two Possible Treatments for Intractable Breast Cancer Type"},"content":{"rendered":"
REDMOND, Washington. \u2014 March 21, 2020 \u2014 Pattern Computer\u00ae<\/sup>, Inc. has received confirmation from Lawrence Berkeley National Laboratory that drug therapy combinations it identified using its proprietary machine learning pattern discovery system are effective in killing malignant breast cancer tumors. Notably, the Pattern Computer team chose to go after basal-like or \u201ctriple negative\u201d breast cancer because it represents 15-20% of breast cancer patients, is aggressive, and has no effective drugs available. For further technical detail, go to https:\/\/www.patterncomputer.com\/news\/lbnl\/<\/a>.<\/p>\n \u201cWe\u2019re very excited by the two-tier bio-validation results we\u2019ve just received for our combination therapy candidates, which we filtered for drugs that were already individually FDA-approved or in process. This was our first project in biotech, and we are hopeful for many future successes along the path to developing a treatment for this and other cancers and diseases,\u201d said Mark R. Anderson, CEO of Pattern Computer.<\/p>\n The two therapy treatments successfully completed final in vitro<\/em> organoid testing at Lawrence Berkeley National Laboratory, demonstrating \u201csignificant synergistic interaction\u201d in killing malignant tumor cells, with statistically \u201clow-to-no adverse effects\u201d on healthy cells. With these results, Pattern Computer will proceed to the next phase of preclinical testing.<\/p>\n \u201cWe appreciate our results are still relatively early; we\u2019re therefore approaching these next steps with due care and caution,\u201d Anderson said, \u201cbut we\u2019re encouraged by the biological validation we are seeing to date of our computational models in this area. We are delighted to be working with Lawrence Berkeley National Labs on confirming these findings.\u201d<\/p>\n About Pattern Computer<\/strong><\/p>\n Pattern Computer, a Seattle-area startup, uses its proprietary Pattern Discovery Engine™<\/sup> to solve the most important and intractable problems in business and medicine. The company\u2019s proprietary mathematical techniques can find complex patterns in very high-order data which have eluded detection by much larger systems.<\/p>\n While the company is currently applying its computational platform to the challenging field of drug discovery, it is also making pattern discoveries for partners in several other sectors, including additional biomedical research, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance.<\/p>\n